{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:35:39Z","timestamp":1792989339383,"version":"4.5.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>An initial decline in estimated glomerular filtration rate (eGFR) is expected after initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed across patients with diabetes, chronic kidney disease, and heart failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the implications of initial changes in eGFR among patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a prespecified analysis of the results of the DELIVER randomized clinical trial, which was an international multicenter study of patients with EF greater than 40% and eGFR greater than or equal to 25. The DELIVER trial took place from August 2018 to March 2022. Data for the current prespecified study were analyzed from February to October 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Dapagliflozin, 10 mg per day, or placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>In this prespecified analysis, the frequency of an initial eGFR decline (baseline to month 1) was compared between dapagliflozin and placebo. Cox models adjusted for baseline eGFR and established prognostic factors were fit to estimate the association of an initial eGFR decline with cardiovascular (cardiovascular death or heart failure event) and kidney (\u226550% eGFR decline, eGFR&amp;amp;lt;15 or dialysis, death from kidney causes) outcomes, landmarked at month 1, stratified by diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Study data from 5788 participants (mean [SD] age, 72 [10] years; 3253 male [56%]) were analyzed. The median (IQR) change in eGFR level from baseline to month 1 was \u22121 (\u22126 to 5) with placebo and \u22124 (\u22129 to 1) with dapagliflozin (difference, \u22123; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). A higher proportion of patients assigned to dapagliflozin developed an initial eGFR decline greater than 10% vs placebo (1144 of 2892 [40%] vs 737 of 2896 [25%]; odds ratio, 1.9; 95% CI, 1.7-2.1; <jats:italic>P<\/jats:italic> difference &amp;amp;lt;.001). An initial eGFR decline of greater than 10% (vs \u226410%) was associated with a higher risk of the primary cardiovascular outcome among those randomized to placebo (adjusted hazard ratio [aHR], 1.33; 95% CI, 1.10-1.62) but not among those randomized to dapagliflozin (aHR, 0.90; 95% CI, 0.74-1.09; <jats:italic>P<\/jats:italic> for interaction\u2009=\u2009.01). Similar associations were observed when alternative thresholds of initial eGFR decline were considered and when analyzed as a continuous measure. An initial eGFR decline of greater than 10% was not associated with adverse subsequent kidney composite outcomes in dapagliflozin-treated patients (aHR, 0.94; 95% CI, 0.49-1.82).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Among patients with HFmrEF or HFpEF treated with dapagliflozin, an initial eGFR decline was frequent but not associated with subsequent risk of cardiovascular or kidney events. These data reinforce clinical guidance that SGLT2is should not be interrupted or discontinued in response to an initial eGFR decline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03619213\">NCT03619213<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.4664","type":"journal-article","created":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T19:30:33Z","timestamp":1699817433000},"page":"144","source":"Crossref","is-referenced-by-count":42,"title":["Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction"],"prefix":"10.1001","volume":"9","author":[{"given":"Finnian R.","family":"Mc Causland","sequence":"first","affiliation":[{"name":"Renal Division, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Desai","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[{"name":"Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fang","sequence":"additional","affiliation":[{"name":"University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, University of Missouri, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Center Singapore and Duke\u2013National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Martinez","sequence":"additional","affiliation":[{"name":"National University of Cordoba, Cordoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F. Kerr","family":"Saraiva","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Instituto de Pesquisa Cl\u00ednica de Campinas, Campinas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina M.","family":"McGrath","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Petersson","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"hoi230066r1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"hoi230066r2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi230066r3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi230066r4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"hoi230066r5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi230066r6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi230066r7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"hoi230066r8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi230066r9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi230066r10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi230066r11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging.","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"hoi230066r12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than preglomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"issue":"11","key":"hoi230066r13","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial.","volume":"29","author":"Wanner","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"hoi230066r14","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/dom.v23.12","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.","volume":"23","author":"Cherney","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"hoi230066r15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020237","article-title":"Clinical implications of estimated glomerular filtration rate dip following sodium-glucose cotransporter-2 inhibitor initiation on cardiovascular and kidney outcomes.","volume":"10","author":"Xie","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"hoi230066r16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate dip upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"hoi230066r17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int"},{"issue":"7","key":"hoi230066r18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1159\/000524889","article-title":"Initial eGFR changes with ertugliflozin and associations with clinical parameters: analyses from the VERTIS CV Trial.","volume":"53","author":"Cherney","year":"2022","journal-title":"Am J Nephrol"},{"issue":"6","key":"hoi230066r19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF.","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"hoi230066r21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial.","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"12","key":"hoi230066r22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"hoi230066r23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"hoi230066r24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial.","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hoi230066r25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"hoi230066r26","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/dom.2018.20.issue-8","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"hoi230066r27","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"issue":"1","key":"hoi230066r28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","article-title":"Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.","volume":"19","author":"Schernthaner","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"hoi230066r20","unstructured":"AstraZeneca. Our transparency commitments. Accessed October 1, 2023. https:\/\/astrazenecagrouptrials.pharmacm.com\/ST\/Submission\/Disclosure"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2811979\/jamacardiology_mc_causland_2023_oi_230066_1716231338.25452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:00:42Z","timestamp":1716390042000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2811979"}},"subtitle":["A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.4664","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}